The magnitude of platelet inhibition and the pharmacokinetics of a 600 mg loading dose of clopidogrel, in different patient categories (stable angina versus acute-coronary syndromes versus ST-elevated myocardial infarction). - The MAPCAT-study

Cardiology0 个研究点目标入组 200 人开始时间: 待定最近更新: 2024年5月13日

适应症

试验速览

暂无简介。

•Group 1: Patients with a history of a stent thrombosis in the period 2002-2009.
•Group 2: Patients with ACS or stable AP.

•Persistent acute ST-segment elevation
•Successful revascularization during the qualifying hospitalization, prior to study entry
•Acute pulmonary edema, hypotension, or evidence of cardiogenic shock
•Clinically significant liver disease
•End stage kidney disease requiring dialysis
•Use at study entry of drugs that are strong inhibitors of cytochrome P450 3A4 and CYP3A5 (i.e. clarithromycin, erythromycin, itraconazole, ketoconazole)
•Contraindications to antithrombotic/antiplatelet therapy
•Failed coronary intervention in the previous 2 weeks
•Malignancies
•Increased risk of bleeding (previous stroke in the past months, active bleeding or bleeding diathesis, recent trauma or major surgery in the last month, suspected aortic dissection, oral anticoagulation therapy with coumarin derivate within 7 days, recent use of GPIIb/IIIa inhibitors within 14 days, severe uncontrolled hypertension >180 mmHg unresponsive to therapy)
•Relevant hematologic deviations ( aemoglobin <100g/L (6,2 mmol/L) or hematocrit <34%, platelet count <100 x 109 /L or platelet count > 600 x 109/L)
•Known allergy to clopidogrel
•Pregnancy (present or suspected)
•Uncontrolled hypertension at time of randomization

发起方

Cardiology